Edition:
India

Urogen Pharma Ltd (URGN.OQ)

URGN.OQ on NASDAQ Stock Exchange Global Market

46.50USD
1:46am IST
Change (% chg)

$0.96 (+2.11%)
Prev Close
$45.54
Open
$46.00
Day's High
$46.80
Day's Low
$45.00
Volume
6,427
Avg. Vol
22,122
52-wk High
$68.91
52-wk Low
$36.66

Latest Key Developments (Source: Significant Developments)

Urogen Pharma Reports Q3 Loss Per Share $1.28
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Urogen Pharma Ltd ::UROGEN PHARMA REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND COMPLETED UGN-101 OLYMPUS TRIAL ENROLLMENT.Q3 LOSS PER SHARE $1.28.Q3 EARNINGS PER SHARE VIEW $-1.05 -- THOMSON REUTERS I/B/E/S.UROGEN PHARMA - ON TRACK TO INITIATE UGN-101 ROLLING NDA SUBMISSION TO FDA IN Q418 WITH COMPLETED SUBMISSION IN Q219 AND POTENTIAL APPROVAL IN 2019.  Full Article

FDA grants breakthrough therapy designation (btd) for Urogen Pharma’S Ugn-101 for the treatment of patients with low-grade upper tract urothelial cancer (lg utuc)
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - Urogen Pharma Ltd ::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION (BTD) FOR UROGEN PHARMA’S UGN-101 FOR THE TREATMENT OF PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER (LG UTUC).UROGEN PHARMA LTD - ON TRACK TO INITIATE ROLLING SUBMISSION OF UGN-101 NEW DRUG APPLICATION (NDA) IN Q4 2018.UROGEN PHARMA LTD - UGN-101 JOINS SELECT GROUP OF UROLOGIC ONCOLOGY PRODUCT CANDIDATES TO RECEIVE BTD.  Full Article

Urogen Pharma Q2 Loss Per Share $1.14
Tuesday, 14 Aug 2018 

Aug 14 (Reuters) - Urogen Pharma Ltd ::UROGEN PHARMA REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS.Q2 LOSS PER SHARE $1.14.Q2 EARNINGS PER SHARE VIEW $-0.89 -- THOMSON REUTERS I/B/E/S.AS OF JUNE 30, 2018, CASH AND CASH EQUIVALENTS TOTALED $119.1 MILLION.  Full Article

Urogen Pharma Appoints Peter P. Pfreundschuh As Chief Financial Officer
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Urogen Pharma Ltd ::UROGEN PHARMA APPOINTS PETER P. PFREUNDSCHUH AS CHIEF FINANCIAL OFFICER.UROGEN PHARMA LTD - STEPHEN MULLENNIX WILL CONTINUE IN HIS ROLE AS COMPANY'S CHIEF OPERATING OFFICER.  Full Article

Urogen Pharma Announces Positive Interim Results From Pivotal Phase 3 Olympus Trial Of UGN-101
Monday, 21 May 2018 

May 21 (Reuters) - Urogen Pharma Ltd ::UROGEN PHARMA ANNOUNCES POSITIVE INTERIM RESULTS FROM PIVOTAL PHASE 3 OLYMPUS TRIAL OF UGN-101 (MITOGEL™) FOR NON-SURGICAL TREATMENT OF UPPER TRACT UROTHELIAL CANCER (UTUC).UROGEN PHARMA LTD - INTERIM RESULTS SHOWED COMPLETE RESPONSE (CR) RATE OF 59 PERCENT IN PATIENTS WITH LOW-GRADE UTUC.UROGEN PHARMA LTD - OLYMPUS TRIAL CONTINUES TO ENROLL PATIENTS, AND TOP-LINE RESULTS ARE EXPECTED IN SECOND HALF OF 2018.UROGEN PHARMA LTD - CRS TO DATE REMAIN DURABLE AT THREE, SIX AND NINE-MONTH FOLLOW-UP IN PHASE 3 OLYMPUS TRIAL OF UGN-101.UROGEN PHARMA LTD - UGN-101 APPEARED TO BE WELL-TOLERATED WITH MOST TREATMENT-EMERGENT ADVERSE EVENTS CHARACTERIZED AS MILD OR MODERATE AND TRANSIENT.  Full Article

UroGen Pharma Reports Q1 Loss Per Share Of $0.88
Tuesday, 15 May 2018 

May 15 (Reuters) - UroGen Pharma Ltd ::UROGEN PHARMA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS.Q1 LOSS PER SHARE $0.88.Q1 EARNINGS PER SHARE VIEW $-0.72 -- THOMSON REUTERS I/B/E/S.  Full Article

Urogen Announces Proposed Public Offering Of Ordinary Shares
Wednesday, 17 Jan 2018 

Jan 16 (Reuters) - Urogen Pharma Ltd ::UROGEN PHARMA ANNOUNCES PROPOSED PUBLIC OFFERING OF ORDINARY SHARES.UROGEN PHARMA SAYS IT HAS FILED WITH U.S. SEC IN CONNECTION WITH A PUBLIC OFFERING OF 1.1 MILLION ORDINARY SHARES.  Full Article

Urogen Pharma Q3 loss per share $0.02
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Urogen Pharma Ltd :Urogen Pharma reports third quarter 2017 financial results and recent corporate developments.Q3 loss per share $0.02.Q3 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S.  Full Article

Menora Mivtachim reports 5.38 pct passive stake in UroGen Pharma ‍​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - UroGen Pharma Ltd -:Menora Mivtachim Holdings Ltd reports 5.38 percent passive stake in UroGen Pharma Ltd as of Nov 1 - SEC filing ‍​.  Full Article

Photo

Israel's UroGen to start mid-stage bladder cancer trial

RAANANA, Israel Israel's UroGen Pharma plans to begin a mid-stage trial of its treatment for bladder cancer patients in August, after positive interim results last month from an advanced trial of a treatment for upper urinary tract cancer.